MBIO.NASDAQMustang Bio, INC

10-Q: Mustang Bio Reports Q1 2025 Financial Results, Cites Going Concern Uncertainty

Sentiment:

Quarterly Report

📋All filings for Mustang Bio, INC
🔒Login to Follow

Mustang Bio reports a net loss of $0.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Delay expectedThe company is exploring with COH and Nationwide the possibility of initiating a clinical trial as an investigator-sponsored single-institution study at COH in the first quarter of 2026.The company is in planning stages for a proof-of-concept investigator-sponsored clinical trial and actively evaluating potential indications in which MB-106 may be most effective and serve a patient population with high unmet need with a potential trial initiation in the first quarter of 2026.
Capital raiseThe company completed a public offering in February 2025, generating net proceeds of approximately $6.8 million.The company states that there is substantial doubt about its ability to continue as a going concern for the next 12 months without raising additional capital.
Worse than expectedThe company states that there is substantial doubt about its ability to continue as a going concern.The company has an accumulated deficit of $396.9 million as of March 31, 2025.

Summary

  • Mustang Bio, a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2025.
  • The company incurred a net loss of $0.2 million, compared to a net loss of $5.2 million for the same period in 2024.
  • Research and development expenses decreased significantly to $(1.0) million from $3.8 million in the prior year, primarily due to workforce reductions and termination of certain agreements.
  • General and administrative expenses decreased slightly to $1.2 million from $1.4 million.
  • As of March 31, 2025, Mustang Bio had cash and cash equivalents of $14.2 million.
  • The company states that there is substantial doubt about its ability to continue as a going concern for the next 12 months without raising additional capital.
  • Mustang Bio is exploring investigator-sponsored trials for MB-109 and MB-106, with potential initiation in Q1 2026.
  • The company completed a public offering in February 2025, generating net proceeds of approximately $6.8 million.
  • A reverse stock split was implemented on January 15, 2025, to regain compliance with Nasdaq listing requirements.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the going concern warning and continued losses, despite some positive developments in reducing expenses and raising capital.

Positives

  • The net loss decreased significantly compared to the same period last year.
  • The company successfully completed a public offering, raising $6.8 million.
  • Mustang Bio regained compliance with Nasdaq listing requirements.
  • The company is progressing with plans for investigator-sponsored trials for MB-109 and MB-106.

Negatives

  • The company expresses substantial doubt about its ability to continue as a going concern.
  • The company has an accumulated deficit of $396.9 million as of March 31, 2025.
  • The company has a history of operating losses and expects to continue incurring losses.
  • The company is subject to SEC regulations that limit the amount of funds it can raise during any 12-month period pursuant to its shelf registration statement on Form S-3.

Risks

  • The company's ability to continue as a going concern is dependent on raising additional capital.
  • The company faces risks associated with clinical development, regulatory approvals, and commercialization of product candidates.
  • The company relies on third parties for manufacturing and clinical trials, which introduces potential risks.
  • The company is subject to intense competition in the biopharmaceutical industry.
  • The company is controlled by Fortress Biotech, which could lead to conflicts of interest.
  • The company is subject to economic and geopolitical conditions that could affect its growth.
  • The company is subject to cyber-attacks, or deficiencies in its or third parties cybersecurity.

Future Outlook

The company expects to incur significant operating losses for the foreseeable future and will require substantial additional financing to develop and commercialize its product candidates. They are exploring investigator-sponsored trials for MB-109 and MB-106, with potential initiation in Q1 2026.

Management Comments

  • The company is exploring with COH and Nationwide the possibility of initiating a clinical trial as an investigator-sponsored single-institution study at COH in the first quarter of 2026.
  • The company is in planning stages for a proof-of-concept investigator-sponsored clinical trial and actively evaluating potential indications in which MB-106 may be most effective and serve a patient population with high unmet need with a potential trial initiation in the first quarter of 2026.

Industry Context

Mustang Bio is operating in the competitive biopharmaceutical industry, focusing on CAR T therapies. The company faces competition from other companies developing treatments for similar indications. The success of Mustang Bio depends on its ability to develop and commercialize its product candidates effectively.

Comparison to Industry Standards

  • It is difficult to compare Mustang Bio's results directly to industry standards due to its early stage and specific focus on CAR T therapies.
  • Comparable companies in the CAR T therapy space include Juno Therapeutics (acquired by Celgene), Kite Pharma (acquired by Gilead), and Novartis (Kymriah).
  • These companies have achieved regulatory approvals and commercial success with their CAR T therapies, setting a high benchmark for Mustang Bio.
  • However, Mustang Bio's pipeline targets different indications and utilizes unique technologies, making direct comparisons challenging.
  • The company's financial performance and progress in clinical trials will be closely watched to assess its competitiveness in the CAR T therapy market.

Related Party Transactions

  • The company issued 67,806 shares to Fortress in connection with the equity financings and recorded expense of approximately $0.2 million in general and administrative expenses related to these shares.
  • The company issued 69,046 shares of common stock to Fortress as the Annual Stock Dividend on January 1, 2025.
  • In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as payables and accrued expenses related party.

Stakeholder Impact

  • Shareholders face potential dilution from future equity offerings.
  • Employees may experience uncertainty due to the company's financial situation.
  • Patients may benefit from the development of new therapies.
  • Suppliers and creditors face potential risks due to the company's going concern uncertainty.

Next Steps

  • Continue clinical development of product candidates.
  • Pursue regulatory approvals for product candidates.
  • Explore investigator-sponsored trials for MB-109 and MB-106.
  • Seek additional funding through corporate partnerships and capital markets fundraising.

Key Dates

DateDescription
March 13, 2015Mustang Bio, Inc. was incorporated.
July 22, 2016Second Amended and Restated Founders Agreement became effective.
October 27, 2017Date of Lease Agreement with WCS 377 Plantation Street, Inc.
May 31, 2024Company filed a shelf registration statement on Form S-3.
May 31, 2024Company entered into an At-the-Market Offering Agreement with Wainwright.
June 12, 20242024 S-3 declared effective.
January 1, 2025Company issued 69,046 shares of common stock to Fortress as the Annual Stock Dividend.
January 15, 2025Reverse Stock Split Amendment filed and became effective.
January 16, 2025Common stock quoted on Nasdaq Capital Market on a post-split basis.
January 31, 2025Effective date of Bill of Sale and Surrender Agreement with AbbVie.
February 5, 2025Company commenced a best efforts public offering.
February 7, 2025Company entered into the First Amendment to the Lease Agreement with WCS 377 Plantation Street, Inc.
February 10, 2025February 2025 Offering closed.
February 10, 2025Company entered into a Bill of Sale and Surrender Agreement with AbbVie Bioresearch Center Inc.
February 10, 2025Company was notified by the Staff that it had regained compliance with the Bid Price Rule.
February 21, 2025Closing of the transactions described in the Sale/Surrender Agreement occurred.
February 26, 2025Company was notified by the Staff that it had regained compliance with the Equity Rule.
February 27, 2025Company announced the relocation of its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts.
March 1, 2025As of this date, 53 patients have been treated in an ongoing Phase 1 clinical trial sponsored by Fred Hutch (ClinicalTrials.gov Identifier: NCT03277729).
March 23, 2025Warrant Stockholder Approval was obtained.
March 28, 2025The 2024 Form 10-K was filed with the SEC.
March 31, 2025End of the quarterly period.
April 2025Certain investors from the February 2025 Offering exercised 1,004,355 pre-funded warrants.
May 14, 2025Date of the report.
Q1 2026Potential initiation of investigator-sponsored trials for MB-109 and MB-106.

Keywords

Mustang Bio, financial results, Q1 2025, going concern, clinical trials, capital raise, reverse stock split, MB-109, MB-106, CAR T therapy, biopharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.